Llwytho...
The CYP3A biomarker 4β‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
AIMS: Tacrolimus is a cornerstone in modern immunosuppressive therapy after kidney transplantation. Tacrolimus dosing is challenged by considerable pharmacokinetic variability, both between patients and over time after transplantation, partly due to variability in cytochrome P450 3A (CYP3A) activity...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Br J Clin Pharmacol |
|---|---|
| Prif Awduron: | , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465334/ https://ncbi.nlm.nih.gov/pubmed/28146606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13248 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|